Demand for synthetic genes outruns capacity in 2027–2028, then re-balances as enzymatic platforms reach commercial scale. The thesis of this report is that capacity, not chemistry, determines the next five years of pricing.
Three transitions drive the forecast. First, **enzymatic synthesis** moves from research-grade to commercial in 2027 with Ansa Biotechnologies, Molecular Assemblies, and DNA Script all crossing the $0.05/base GMP threshold. Second, **demand from cell & gene therapy CDMOs** doubles between 2026 and 2029 as commercial AAV programs ramp. Third, **regional capacity divergence** — APAC capacity grows 4.1× while N. American capacity grows 1.8× — pulls a disproportionate share of low-cost research-grade synthesis offshore.
All values in USD billions. Forecast methodology in §11. Includes both research-grade and GMP-grade gene synthesis services; excludes captive in-house synthesis.
CAGR of 25.1% over the forecast horizon. Inflection in 2028 reflects enzymatic platform commercialization; deceleration in 2030 reflects mid-decade capacity overshoot.
| Application segment | 2026 share | 2031 share | 5-yr CAGR |
|---|---|---|---|
| Therapeutic / GMP gene synthesis | 28% | 37% | +30.6% |
| Research-grade synthesis | 41% | 32% | +19.4% |
| Diagnostic & companion Dx panels | 12% | 13% | +25.7% |
| Synthetic biology & strain engineering | 11% | 12% | +27.1% |
| Agricultural & industrial genomics | 8% | 6% | +18.3% |
| Vendor | HQ | 2026 share | Capability |
|---|---|---|---|
| Twist Bioscience | South San Francisco, CA | 26.2% | Silicon-array · GMP |
| Integrated DNA Technologies (Danaher) | Coralville, IA | 18.4% | Phosphoramidite · GMP |
| GenScript ProBio | Piscataway, NJ | 11.7% | GMP CDMO · oligo-pool |
| Eurofins Genomics | Ebersberg, DE | 6.9% | Research-grade · scale |
| Ansa Biotechnologies | Berkeley, CA | 4.3% | Enzymatic · long-read |
| DNA Script | Paris, FR | 3.1% | Enzymatic · benchtop |
| Codex DNA / Telesis Bio | San Diego, CA | 2.8% | Automated benchtop |
| Other (28 vendors) | — | 26.6% | Long tail |
Phosphoramidite is not going away. It is going to specialty applications. Enzymatic owns long-read commodity within five years.
APAC's capacity trajectory is dominated by **GenScript ProBio's Nanjing expansion**, **WuXi Biologics' Wuxi GMP build-out**, and three earlier-stage players (Synbio Technologies, GenoFAB, Tsingke Biotechnology) collectively adding 1.4M bp/day of capacity by Q4 2028. The displacement effect on N. American research-grade pricing will be pronounced — Twist's research-grade ASP drops 38% over the forecast, even as its GMP-grade ASP rises 12%.
End of viewable pages · 178 further pages stream on demand